MAPK4 and prostate carcinoma: MAPK4, members of signaling pathways involved in the development of MM, has been identified as a tumor suppressor that is down-regulated and in various adenocarcinomas or cancers, such as pancreatic adenocarcinoma [49], breast and prostate cancer [50].